Venous Occlusion Does Not Release von Willebrand Factor, Factor VIII or PAI-1 from Endothelial Cells – The Importance of Consensus on the Use of Correction Factors for Haemoconcentration

• References

• 1 Nicoloso G, Hauert J, Kruithof EKO, Van Melle G, Bachmann F. Fibrinolysis in normal subjects – comparison between plasminogen activator inhibitor and other components of the fibrinolytic system. Thromb Haemostas 1988; 59: 299-303
• 2 Jennings I, Luddington RJ, Harper PL. Changes in endothelial-related coagulation proteins in response to venous occlusion. Thromb Haemostas 1991; 65: 374-376
• 3 Ponari O, Pini M, Poli T, Poti R, Dettori AG. Correlation between changes induced by venous occlusion on factor VIII-von Willebrand factor components and fibrinolytic activity. Haemostasis 1984; 14: 179-183
• 4 Dettori AG, Pini M, Megha A, Portioli D, Ponari O. Studies on the haemostatic system in peripheral arterial disease. Variations in factor VIII components (FVIII:C; FVIIIR:Ag; FVIII:WF) before and after venous occlusion. Thromb Res 1981; 22: 559-564
• 5 Korninger Ch, Niessner H, Lechner K. Impaired fibrinolytic response to DDAVP and venous occlusion in a subgroup of patients with von Willebrand’s disease. Thromb Res 1981; 23: 365-374
• 6 Juhan-Vague I, Conte-Devolx B, Aillaud MF, Mendez C, Olivier C, Collen D. Effects of DDAVP and venous occlusion on the release of tissue-type plasminogen activator and von Willebrand factor in patients with panhypopituitarism. Thromb Res 1984; 33: 653-659
• 7 Kruithof EKO, Nicoloso G, Bachmann F. Plasminogen activator inhibitor 1: development of a radioimmunoassay and observations on its plasma concentration during venous occlusion and after platelet aggregation. Blood 1987; 70: 1645-53
• 8 Nilsson IM, Robertson B. Effect of venous occlusion on coagulation and fibrinolytic components in normal subjects. Thromb Diathes Haemorrh 1968; 29: 397-408
• 9 Nguyen G, Horellou MH, Kruithof EKO, Conard J, Samama M. Residual plasminogen activator inhibitor activity after venous stasis as a criterion for hypofibrinolysis: a study in 83 patients with confirmed deep vein thrombosis. Blood 1988; 72: 601-605
• 10 Gris JC, Schved JF, Raffanel C, Dubois A, Aguilar-Martinez P, Arnaud A, Sanchez N. Impaired fibrinolytic capacity in patients with inflammatory bowel disease. Thromb Haemostas 1990; 63: 472-475
• 11 Chan TK, Chan V. The effect of venous occlusion on antithrombin III, plasminogen activator and fibrinogen degradation product (fragment E) levels. Thromb Res 1979; 15: 525-534
• 12 Grignani G, Gamba G, Geroldi D, Pacchiarini L, Solerte B, Ferrari E, Ascari E. Enhanced antithrombotic mechanisms in patients with maturity-onset diabetes without thromboembolic complications. Thromb Haemostas 1981; 46: 648-651
• 13 Keber D. On the use of different correction factors for haemoconcentration. Thromb Haemostas 1983; 49: 245
• 14 Robertson B, Pandolfi M, Nilsson IM. Response of local fibrinolytic activity to venous occlusion of arms and legs. Acta Chir.Scand 1972; 138: 437-440
• 15 Kluft C, Verheijen JH. Leiden Fibrinolysis Working Party: blood collection and handling procedures for assessment of tissue-type plasminogen activator (t-PA) and plasminogen activator inhibitor (PAI-1). Fibrinolysis 1990; 4: 155-161
• 16 MacGregor IR, MacDonald S, Dawes J, Michelin LR, James K. A monoclonal antibody enzyme linked immunoabsorbent assay (ELISA) directed towards a fibrin binding region of tissue-plasminogen activator. Fibrinolysis 1987; 1: 247-252
• 17 MacGregor IR, Booth NA. An enzyme-linked immunoabsorbent assay (ELISA) used to study the cellular secretion of endothelial plasminogen activator inhibitor (PAI-1). Thromb Haemostas 1988; 59: 68-72
• 18 Booth NA, Simpson AJ, Croll A, Bennett B, MacGregor IR. Plasminogen activator inhibitor (PAI-1) in plasma and platelets. Br J Haematol 1988; 70: 327-333
• 19 Machin SJ, Mackie IJ. Haemostasis. In: Laboratory Haematology. An Account of Laboratory Techniques. Chanarin I. (ed). Churchill Livingstone; Edinburgh: 1989: 263-395